Notably, TG2 expression has recently been linked to immunosuppression in pancreatic cancer, correlating with upregulation of immunomodulatory cells and exclusion of effector cells, in mechanisms involving NF-kB and the regulation of programmed death ligand-1 (PD-L1) [153], and TG2 has been identified in an immune signature associated with poor prognosis in lung squamous cell carcinoma [99]. The gene discussed is TGM2; the disease is squamous cell lung carcinoma.